In the article titled “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium” [1], there were errors in the description of Figure 1 and Table 1. The last sentence of Figure 1 should be updated from “LABA, long-acting β2-agonist” to “IL, interleukin; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β2-agonist.” In addition, the last sentence of Table 1 should be updated from “LABA, long-acting β2-agonist; N/A, not applicable; NR, not reported; NS, not significant" to “ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; N/A, not applicable; NR, not reported.”
Corrigendum | Open Access
Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
Received06 Jan 2019
Accepted08 Jan 2019
Published29 Jan 2019
References
E. Hamelmann, “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium,” BioMed Research International, vol. 2018, Article ID 7473690, 9 pages, 2018.
View at: Publisher Site | Google Scholar
Copyright
Copyright © 2019 Eckard Hamelmann. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.